An interventional study of CorFlow Controlled Flow Infusion System - CoFI™ in Microvascular Obstruction (MVO), STEMI - ST Elevation Myocardial Infarction and PPCI, sponsored by CorFlow Therapeutics AG. Recruiting at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by CorFlow Therapeutics AG · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in ST Elevation Myocardial Infarction with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.
Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 22nd largest by planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2025, is one of 23 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 82nd registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →6 of the 83 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
TherOx · Sites in United States
Ages 18–80
Nabeel Hamzeh · Sites in United States
Ages 18+ · Healthy volunteers
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
Life Recovery Systems · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 9 · Phase 4 8
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 236 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 101 across the 56 interventional studies, 324 across the 27 observational. Of the 60 that completed or were terminated, 26 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 83 have an industry lead sponsor. The 10 most frequent:
CorFlow Therapeutics AG is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
CorFlow Therapeutics AG has 3 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in ST Elevation Myocardial Infarction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06909578CorFlow Therapeutics AGMicrovascular Obstruction Diagnosis Using the CoFI™ System Assessment - II | 2026-12-31 |
| NCT06438315TherOxSuperSaturated Oxygen Comprehensive Observational Registry | 2027-03 |
| NCT05284747AmgenEVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | 2027-05-29 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations.
Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.
Microvascular obstruction (MVO) is a common complication that occurs after establishing coronary vessel patency by percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI).
Despite the successful restoration of vessel patency through PCI, 50% to 70% of STEMI subjects experience MVO, which affects vessels in the myocardial microcirculation. MVO occurs most commonly in the setting of AMI because the prolonged ischemia leads to endothelial damage, myocyte oedema and micro-vascular dysfunction.
Research has shown that MVO increases the risk of poor clinical outcomes, including death, re-infarction, reduced left ventricular ejection fraction (LVEF), left ventricular (LV) remodeling, heart failure, and more.
Late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) is the current state-of-the-art for MVO identification and quantification. However, due to clinical reasons, CMRI imaging cannot be performed during the subject's emergent state. In most cases, this means that the diagnosis is made outside the biological window where MVO-related damage to heart muscle could be reversed or at least reduced.
Thus, although CMRI is the most accurate method to diagnose MVO, its use in routine practice is limited. Therefore, a direct and accurate quantitative diagno-sis during primary PCI is required for early risk stratification in routine clinical practice.
The Controlled Flow Infusion (CoFI) system is designed to be integrated into current PCI protocols, enabling the rapid and safe detection of MVO after successful PCI procedures. Using a proprietary algorithm, the system can provide an output for diagnosing microvascular obstruction (MVO) immediately post-PCI by measuring real-time distal coronary back-pressure response to a dynamic infusion sequence downstream of a low-pressure occlusion balloon.
The aim of the study is to validate the pCoFI threshold of 124 mmHg to be an accurate diagnostic method for the detection of MVO in STEMI subjects following PPCI as measured in CMRI 1-3 days post-procedure.
Phase 1 is designed to evaluate the CoFI system and associated study procedures at up to eight selected sites across the United States and Europe. A minimum of 15 subjects per protocol will be included, with enrollment of up to 20 subjects.
Following analysis of the subject data in Phase 1 and confirmation to proceed by the DSMB the study will progress to Phase 2, the pivotal Phase. The aim of Phase 2 is to confirm the study hypothesis and the primary efficacy and safety endpoints to be met.
The sample size for the MOCA II Phase 2 is based on a conservative assumed prevalence of 50% MVO+. A one-time, blinded sample size re-estimation will be conducted after approximately 50% of the initially planned Phase 2 evaluable subjects have completed CMRI assessment (1-3 days after PPCI). The observed CMRI-derived prevalence of MVO+ will be used to update the assumed prevalence (i.e 50%) and recalculate the total required sample size. The final Phase 2 analysis will be conducted following confirmed database lock and ap-proval to proceed by the study DSMB.
The analyses in Phase 1 and Phase 2 will be done independently of each other. The Phase 1 analysis will be conducted by statistician (A), while statistician (B) will perform the Phase 2 analyses.
The criteria were revised on the registry on Nov 20, 2026. See what changed
Clinical:
1. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation.
Exclusion Criteria
Clinical:
to CMRI
PPCI \& Angiographic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: CorFlow Controlled Flow Infusion System - CoFI™
The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
Primary Effectiveness Endpoint
Diagnostic performance is measured using the two co-primary endpoints, sensitivity and specificity of the CoFI system in detecting MVO in relation to the pre-set pCoFI threshold of 124 mmHg. The analysis will be per-protocol (PP) (primary) and the full analysis set (FAS) (secondary). The control is by LGE CMRI. Hypothesis Both Sensitivity and Specificity will be tested to meet the acceptance criteria: i. The lower bound of the 95% confidence interval (CI) for sensitivity is ≥ 70% ii. The lower bound of the 95% CI for specificity is ≥ 65% These co-primary endpoints are evaluated under a joint hypothesis-testing framework. Primary Safety Endpoint Composite of device- or procedure-related mortality, clinically driven target vessel/lesion revascularization, stent thrombosis and device- or procedure related vessel dissection assessed at 30 days, as adjudicated by the CEC.
Time frame: From enrollment to the end of treatment at 6 Months
Plan to share: No — Decide has to made by study leadership.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 145 interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 15 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
CorFlow Therapeutics AG